Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

December 01, 2011 (Vol. 31, No. 21)

Reimbursement in Personalized Medicine

Payer Acceptance of Molecular Diagnostics Remains a Constant Battle with No Relief in Sight

  • Gaining acceptance for the molecular diagnostics that are the hallmark of personalized medicine is like hand-to-hand combat, according to Steven Burrill, CEO of Burrill & Company. Speaking at the “Burrill Personalized Medicine” meeting in San Francisco recently, he and other presenters outlined the significant challenges companies are facing in ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.